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Excessive renal sympathetic nerve activity has been pro-posed to be a final common pathway for the genesis of 
hypertension,1 the largest global contributor to premature 
death.2 The sympathetic nervous system seems to be espe-
cially important in individuals with an exaggerated response to 
dietary NaCl (salt-sensitive hypertensives), whether this results 
from genetic3 or acquired factors.4,5 Norepinephrine infusion in 
animals reduces urinary sodium excretion and increases blood 
pressure,6–8 but these effects may not reflect direct stimulation 
of salt reabsorption by renal tubules. Renal nerves also stimu-
late renin secretion, which increases sodium reabsorption and 
raises blood pressure via the actions of angiotensin II and aldo-
sterone. Additional effects of the sympathetic nervous system 
on the renal vasculature may also contribute by altering renal 
hemodynamics. Where direct stimulation of Na+ reabsorption 
by tubules has been invoked, it is generally accepted that 
α-adrenergic receptors mediate these effects.1
More recently, Mu et al8 reported that chronic adrenergic 
activation, by norepinephrine or isoproterenol, causes salt-
sensitive hypertension by activating the thiazide-sensitive 
NaCl cotransporter (NCC) in the kidney; they postulated 
that this effect was mediated by glucocorticoid-dependent 
effects on WNK kinases, specifically serine/threonine-protein 
WNK4. WNK effects are mediated primarily by the activation 
of 2 kinases, STE20/SPS1-related proline- and alanine-rich 
kinase (SPAK; STK39) and oxidative stress–response kinase 
1 (OxSR1; OxSR1, often termed OSR1; because OSR1 is the 
official gene symbol for odd-skipped related 1, we have used 
the term OxSR1 for clarity). These findings have been con-
troversial, because some aspects were not corroborated by 
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another group,7 and other mediators, such as angiotensin II, 
were felt likely to have contributed.9 Interestingly, however, a 
little-cited study published >30 years ago, using micropuncture 
techniques, reported that acute isoproterenol infusion stimu-
lated salt transport along the distal convoluted tubule (DCT).10 
Additionally, the work of Morel11 on adenylyl cyclase activities 
in microdissected nephron segments showed that the early dis-
tal tubule (corresponding to the DCT) of the rat is isoprotere-
nol-responsive. If confirmed, these results would provide novel 
mechanistic insights linking salt and the adrenergic nervous 
system that are likely to have therapeutic implications.
During the past 10 years, interest in renal sympathetic con-
trol has surged, because technical advances have made renal 
denervation popular for treating resistant hypertension.12 
Substantial effects of renal nerve ablation on arterial pressure 
have been observed in many studies, using a variety of experi-
mental models1; early success in clinical trials13 led to wider 
adoption of the technique in Europe and high anticipation for 
Food and Drug Administration approval in the United States. 
The recent announcement that the large randomized renal 
denervation trial, SYMPLICITY HTN-3,14 did not reach its 
primary efficacy end point, when compared with sham treat-
ment, was disappointing, but it suggests that maximal medical 
treatment of humans, as achieved in this trial, may interrupt 
many of the pathways activated by renal nerves.
Although excessive activity of NCC is known to cause 
hypertension in patients with the Mendelian disease, familial 
hyperkalemic hypertension (pseudohypoaldosteronism type 
2),15–17 many investigators suggest that such monogenic syn-
dromes are not relevant for typical hypertension.18 In common 
forms of hypertension, however, a role for NCC is suggested 
by the substantial clinical efficacy of NCC inhibitors, thiazide 
diuretics, to treat hypertension. In fact, it is often forgotten 
that these drugs seem to be effective only when hypertension 
is present; they have little or no effect on arterial pressure in 
normotensive individuals, but reduce it substantially in hyper-
tensive patients.19–21 Therefore, it would be appealing to find 
a link between sympathetic overactivity and activated NCC. 
Here, we confirmed that NCC is activated in salt-sensitive 
hypertension resulting from adrenergic stimulation. Because 
sympathetic nerve effects are typically rapid, we developed 
an acute model of adrenergic stimulation, permitting us to 
study signaling mechanisms in vivo in the absence of chronic 
compensation. This allowed us to confirm the involvement of 
β-adrenergic receptors and establish that activation is medi-
ated by an atypical signaling pathway in the DCT.
Methods
See Methods in the online-only Data Supplement.
Results
To confirm the effects of chronic adrenergic stimulation on 
blood pressure, we infused mice with norepinephrine via 
osmotic minipump for 2 weeks according to the protocol pre-
viously described.8 Norepinephrine infusion increased sys-
tolic blood pressure slightly while mice consumed a normal 
salt diet (0.49% NaCl); when the mice consumed a high-salt 
diet (8% NaCl) with continued norepinephrine infusion, how-
ever, systolic pressure increased substantially (Figure 1A). In 
vehicle-infused mice, high salt intake did not affect pressure. 
Norepinephrine also increased the abundance of NCC and 
phosphorylated (activated) NCC (pNCC; Figure 1B and 1C; 
Figure S1A and S1B in the online-only Data Supplement). 
These results are similar to those reported previously by oth-
ers,8 although we did not detect changes in the abundance of 
the NCC regulatory kinase WNK4, at least at the protein level 
(Figure 1C; Figure S1C).
Although these results confirm that chronic norepinephrine 
administration increased blood pressure and activated NCC, the 
effects may not have been direct. To develop an in vivo approach 
that limits compensatory changes, we determined norepineph-
rine effects 30 minutes after administration. Indeed, pNCC 
was increased at this time point; in contrast, and as expected, 
total NCC abundance remained unchanged (Figure 2A and 
2B; Figure S2A–S2E). To determine whether norepinephrine 
activation of NCC requires angiotensin II, a known NCC acti-
vator,22,23 angiotensin II receptor type 1a knockout mice were 
treated with norepinephrine. These animals have normal NCC 
and pNCC abundance at baseline (Figure 2C; Figure S2F and 
S2G), and the effect on pNCC 30 minutes after norepinephrine 
treatment was preserved (Figure 2D; Figure S2H and S2I).
To test whether α- or β-receptors were responsible for rapid 
NCC activation, we used the α1-specific agonist phenyleph-
rine and the β1/β2-specific agonist isoproterenol. Stimulation 
of α1-receptors with phenylephrine did not increase pNCC 
significantly (Figure 3A; Figure S3A and S3B), whereas 
isoproterenol-mediated stimulation of β-receptors did 
(Figure 3B; Figure S3C and S3D). Simultaneous stimulation 
of α1- and β- adrenergic receptors with both phenylephrine 
and isoproterenol increased pNCC more than either agonist 
alone, suggesting a potential interaction of receptor subtypes 
(Figure 3C; Figure S3E and S3F).
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Figure 1. Confirmation that chronic norepinephrine (NE) 
infusion causes salt-sensitive hypertension and increases NaCl 
cotransporter (NCC) and phosphorylated NCC (pNCC). A, NE 
infusion caused salt-induced hypertension. During week 1, all 
animals were maintained on a normal salt diet without infusion. 
NE or control infusion (Con) was started during week 2, whereas 
normal salt diet was continued. During week 3, both groups were 
switched to a high-salt diet; n=6 per group. Differences were 
determined by 2-way ANOVA with repeated measures, where  
P values are 0.0018 for time, 0.0073 for treatment (NE vs Con), 
and 0.0119 for interaction. B, NE infusion caused an increase in 
NCC abundance compared with control mice; n=4 per group; 
P<0.05 by unpaired t test. C, NE infusion caused an increase 
in pNCC-T53 abundance compared with control mice (P<0.05 
by unpaired t test); however, WNK4 abundance remained 
unchanged; n=5 per group. Representative images are shown. 
See the online-only Data Supplement for densiometry.
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Although a role for adrenergic receptors in modulating 
renal renin release is well documented, the role and nature of 
adrenergic receptors on distal nephron cells is not as clear. We 
first tested whether DCT cells express β-adrenergic receptors 
by isolating DCT cells from kidney cortex of mice expressing 
green fluorescent protein only in the DCT using a fluorescent 
sorting technique, described previously.24 RNA isolated from 
whole kidney and DCT was then used for reverse transcription 
polymerase chain reaction. Although both β1- and β2-receptors 
were detected (Figure 4A), β1-receptors were highly enriched 
in DCT cells. In contrast, β2-receptors were not, consistent 
with the results of an unbiased genetic screen of the same 
cells.25 When isolated DCT cells were exposed ex vivo to iso-
proterenol, pNCC increased after 10 minutes (Figure 4B).
Mu et al8 suggested that the WNK kinase pathway is 
involved in chronic adrenergic effects on NCC. WNKs sig-
nal NCC predominantly via SPAK, the major serine/threo-
nine kinase that phosphorylates and activates NCC. To test 
whether adrenergic agonists activate SPAK, we examined the 
effects of norepinephrine on SPAK abundance and cellular 
localization. Norepinephrine administration did not affect 
SPAK localization within DCT cells and did not increase 
SPAK abundance, at least within 30 minutes (Figure 5A and 
5B; Figure S4A). It also did not cause an isoform switch, 
which corresponds to SPAK activation.26,27 These results, 
however, do not indicate whether SPAK is necessary for nor-
epinephrine to stimulate NCC. Thus, we tested the effects of 
norepinephrine in SPAK−/− mice. Although pNCC abundance 
at baseline is low in these mice,26,27 pNCC increased robustly 
(Figure 5C and 5D; Figure S4B). In fact, the proportional 
increase in pNCC abundance was larger in SPAK−/− mice than 
in wild-type mice (Figure S4C).
Because OxSR1 has also been shown to phosphorylate NCC 
in vitro,28 and it is expressed along the DCT, we tested whether 
norepinephrine alters its cellular localization. In both wild-
type and SPAK−/− mice, norepinephrine strikingly altered cel-
lular OxSR1 appearance by immunofluorescence (Figure 6). 
Treatment with norepinephrine caused a striking increase in 
apical OxSR1, which assumed a ribbon-like appearance near 
the apical membrane of the DCT. This was especially obvious 
in the SPAK−/− mice, because OxSR1 assumes a distinctive 
punctate pattern in SPAK−/− mice, at baseline26,27,29 (Movie S1).
Although these results suggested a role for OxSR1 in medi-
ating the effects of norepinephrine, they do not prove that 
it is essential. To determine whether OxSR1 is essential for 
increasing the abundance of pNCC, we generated doxycycline-
inducible kidney-specific OxSR1−/− mice. Total-body OxSR1 
is embryonic-lethal, so we deleted OxSR1 along the nephron 
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Figure 2. Norepinephrine (NE) rapidly increases 
phospholyrated NaCl cotransporter (pNCC) 
independent of angiotensin II signaling. A, 
Treatment with NE for 30 min increased pNCC-T53 
abundance, but did not alter total NCC; n=8 per 
group; P<0.05 by unpaired t test. B, Increased 
pNCC-T53 abundance could also be observed 
by immunofluorescence staining. Staining was 
performed on 3 mice per group. C, Genetic deletion 
of the angiotensin II receptor type 1a (AT1a) does 
not alter NCC or pNCC-T53 abundance compared 
with wild-type (WT) controls; n=7 per group. 
D, Treatment with NE for 30 min in AT1a
−/− mice 
increased pNCC-T53 compared with control 
animals; P<0.05 by unpaired t test. Total NCC 
abundance remained unchanged; n=5 per group. 
Representative images are shown. See the online-
only Data Supplement for densiometry.
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Figure 3. β-Receptors mediate the effects of 
norepinephrine on NaCl cotransporter (NCC). 
A, Treatment with the α-receptor agonist 
phenylephrine (PE) for 30 min did not significantly 
increase pNCC-T53. Total NCC abundance also 
remained unchanged; n=5 per group. B, Treatment 
with the β-receptors agonist isoproterenol (Iso) 
for 30 min significantly increased pNCC-T53 
abundance; P<0.05 by unpaired t test. Total NCC 
abundance remained unchanged; n=4 per group. 
C, Treatment with both agonists together increased 
pNCC-T53 abundance greater than either agonist 
alone; P<0.016 by unpaired t test. Total NCC 
abundance remained unchanged; n=5 for the 
control and Iso groups and n=4 for the Iso plus PE 
group. See the online-only Data Supplement for 
densiometry.
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using the Pax8 LC1 system (Figure 7A; Figure S5A). After dele-
tion of OxSR1, these mice have normal NCC abundance (both 
total and phosphorylated; Figure 7B; Figure S5B and S5C). 
Thirty minutes after norepinephrine administration, pNCC 
abundance increased in these mice, but in contrast to the previ-
ously performed experiments, the increase was severely blunted 
(Figure 7C; Figure S5D and S5E). This suggests that OxSR1 is 
essential for the full effect of norepinephrine on NCC.
Discussion
The sympathetic nervous system plays a central role in human 
blood pressure control. Sympathetic nerves to the kidney con-
tribute importantly to these effects by stimulating renal renin 
release, modulating renal vascular tone, and activating NaCl 
transporters.1 Ablating renal sympathetic nerves is an old 
approach to resistant hypertension that has recently regained 
favor, owing to technical advances, which make it easier and 
safer. In many animal and human studies, this approach has 
reduced arterial pressure substantially12; yet a rigorous and 
large clinical trial recently could not confirm that renal dener-
vation is superior to standard care. Thus, although renal dener-
vation reduces blood pressure in models of hypertension, its 
role in clinical medicine remains to be established.
Here, we confirmed that norepinephrine causes salt-sensitive 
hypertension in mice, in part, by activating salt reabsorption 
along the distal nephron via NCC. We show that the effects of 
norepinephrine on NCC activity occur rapidly and are largely 
mediated via β-adrenergic receptors; we also identify a novel 
role for OxSR1 in stimulating NCC in response to stress. 
Although this inquiry has largely focused on the abundance of 
pNCC, our immunofluorescence data also suggest that norepi-
nephrine may induce a translocation of NCC from the cytosol 
to the apical membrane (Figure 2B), as reported previously 
for angiotensin II.22 In our acute studies, we could not mea-
sure salt transport directly, but the abundance of pNCC is used 
widely as a surrogate for NCC activity.23,30 Furthermore, Mu 
et al8 reported that thiazide treatment reverses norepinephrine-
induced hypertension, supporting a functional role for NCC 
activity in these effects. The finding that reducing salt intake 
relowers pressure during continued norepinephrine infusion8 
further supports the importance of salt and is consistent with 
the effects of salt loading in several other experimental mod-
els.31 The current results clarify the important role that NaCl 
reabsorption plays in the effects of norepinephrine on arterial 
pressure and suggest one reason that SYMPLICITY HTN-3 
may have failed to achieve its primary goal.
The nature of the direct and indirect effects of adrenergic 
stimulation on the kidney has been debated for many decades. 
Here, we show that the effect of norepinephrine to increase 
pNCC rapidly is fully preserved in mice lacking angiotensin 
II receptor type 1a, indicating that the effect is not mediated 
by renin or angiotensin II. The effect seems to be mediated 
instead through β-adrenergic receptors, as observed previously 
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alanine-rich kinase (SPAK) is not essential for 
the rapid effects of norepinephrine (NE) on NaCl 
cotransporter (NCC). A, Treatment with NE for 
30 min did not alter SPAK cellular localization 
within the DCT in wild-type animals. Staining was 
performed on 3 mice per group. B, Treatment with 
NE for 30 min did not alter SPAK abundance in 
wild-type animals; n=3 per group. C, Treatment 
with NE for 30 min in SPAK−/− animals significantly 
increased pNCC-T53 abundance; P<0.05 by 
unpaired t test. Total NCC protein remained 
unchanged; n=5 per group. D, Increased 
pNCC-T53 abundance in SPAK−/− animals could 
also be observed by immunofluorescence staining. 
Staining was performed on 3 mice per group. See 
the online-only Data Supplement for densiometry.
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Figure 4. Distal convoluted tubule (DCT)–specific reverse 
transcription polymerase chain reaction (RT-PCR) for β-
adrenergic receptor subtypes. A, RT-PCR on fluorescence 
dissected DCT cells indicated that both β1- and β2-adrenergic 
receptors are expressed in the DCT, but the β1-receptor subtype 
is highly enriched. The template used for RT-PCR was either 5 
ng complementary DNA (cDNA) produced from RNA extracted 
from total kidney (TK) or fluorescence dissected DCT cells (DCT). 
In place of template cDNA, negative control reactions contained 
either the product from a cDNA reaction using DCT RNA that 
lacked reverse transcriptase (−RT) or H2O. β1AR indicates 
β1-adrenergic receptor; β2AR, β2-adrenergic receptor; AQP2, 
aquaporin-2; Con, control; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase; and NCC, NaCl cotransporter. B, Ex vivo 
treatment of fluorescence dissected DCT cells with isoproterenol 
(Iso) for 10 min increased pNCC-T53 abundance, but did not 
alter total NCC; n=4 per group. A.U. indicates arbitrary units. 
Graphs depict mean±SEM; *P<0.05 by unpaired t test.
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during chronic treatment.8 Yet, we also detected evidence for 
synergistic interactions between α- and β-adrenergic recep-
tors to stimulate NCC, a finding compatible with previously 
contradictory results. Although we find that both β1- and β2-
adrenergic receptor subtypes are expressed in the DCT, β1-
receptors were highly enriched, suggesting that they play a 
dominant role. This is consistent with anatomic studies per-
formed in the 1970s and 1980s by Barajas et al.32,33 Taken 
together, our results suggest that NCC can be modulated 
rapidly by direct β-adrenergic input to DCT cells, probably 
enhanced by concomitant α-adrenergic stimulation.
Although many groups have observed that norepinephrine 
infusion increases blood pressure, especially in the setting of 
dietary NaCl loading,7,8 the effects of this treatment on NCC 
and pNCC abundance, as well as WNK signaling cascade 
activity, have been more controversial. Our data here confirm 
that norepinephrine infusion chronically increases both NCC 
and pNCC and raises arterial pressure, as shown previously by 
Mu et al.8 Uchida et al7 confirmed the blood pressure effects 
of norepinephrine infusion with dietary salt loading, but could 
not detect the effects on NCC and WNK4. Although the rea-
sons for these discrepancies are not clear, acute hypertension 
or dietary salt loading typically downregulates NCC34,35; thus, 
the absence of this effect during norepinephrine infusion noted 
by Uchida et al7 likely reflects abnormal NCC activation.
NCC and the furosemide-sensitive Na-K-2Cl cotransporter 
are stimulated by a signaling cascade that includes WNK 
kinases, SPAK and OxSR1. We found no change in WNK4 
abundance on norepinephrine stimulation, using an antibody 
validated against WNK4-knockout tissue, suggesting that 
WNK4 is not involved. Similarly, we found no apparent effect 
of norepinephrine on SPAK. SPAK deletion strikingly reduces 
the abundance of pNCC in vivo,26,27,36,37 whereas OxSR1 dele-
tion does not.38 This has led to a simple paradigm in which 
SPAK, and not OxSR1, was viewed as responsible for acti-
vating NCC.26,38 Surprisingly, adrenergic stimulation induced 
a shift in OxSR1 toward the apical membrane of DCT cells, 
where it might be expected to phosphorylate and activate NCC 
(Figure 8). This apical redistribution occurs whether or not 
SPAK is present, suggesting that this does not require SPAK/
OxSR1 interactions. Because OxSR1 is capable of phosphor-
ylating cation chloride cotransporters in vitro,39 this suggests 
that OxSR1 plays an essential and nonredundant role in the 
adrenergic response. In confirmation of this, inducing OxSR1 
deletion along the nephron, which did not affect basal pNCC 
abundance, strikingly blunted the ability of norepinephrine to 
increase pNCC.
A role for OxSR1 in regulating NCC was suggested by 
Chiga et al,40 who reported that OxSR1 kinase activity is 
required for the full familial hyperkalemic hypertension phe-
notype. They found that disrupting SPAK kinase activity did 
Control NE
WT
SPAK -/-
Figure 6. Norepinephrine (NE) increased distal convoluted 
tubule (DCT) oxidative stress–response kinase 1 (OxSR1) apical 
localization in both wild-type (WT) and STE20/SPS1-related 
proline- and alanine-rich kinase (SPAK)–deficient (SPAK−/−) mice. 
Treatment with NE for 30 min increased the apical localization of 
OxSR1 in the DCT of both WT and SPAK−/− mice. Insets are high-
magnification images of the represented tubule sections. Staining 
was performed on 3 mice per group.
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Figure 7. Kidney-specific (KS) oxidative stress–response kinase 
1 (OxSR1)–deficient (OxSR1−/−) mice exhibited a diminished 
response to norepinephrine (NE). A, KS OxSR1−/− mice had 
significantly decreased abundance of OxSR1 in their kidneys 
compared with wild-type (WT) controls; n=3 per group; P<0.05 
by unpaired t test. B, Abundance of NaCl cotransporter (NCC) 
protein and phosphorylation at threonine-53 was unaltered in KS 
OxSR1−/− mice at baseline; n=3 per group. C, KS OxSR1−/− mice 
exhibited a blunted response to a 30-min treatment with NE. 
NCC phosphorylation at threonine-53 increased in these mice, 
but to a lesser degree than that observed in wild-type controls; 
P<0.05 by unpaired t test; n=3 for WT per group mice and 4 
for KS OxSR1−/− mice per group. C, Control (C) representative 
images are shown. See the online-only Data Supplement for 
densiometry.
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Figure 8. Model of norepinephrine (NE) effects on STE20/SPS1-
related proline- and alanine-rich kinase (SPAK) and oxidative 
stress–response kinase 1 (OxSR1) in the distal convoluted tubule. 
Cartoon shows effects of NE on SPAK (red) and OxSR1 (green) 
distribution in wild-type mice (left two panels). Note that OxSR1, 
but not SPAK, shifts to an apical location. The right panels show 
effects of NE on OxSR1 in SPAK-knockout (KO) mice. Notice that 
SPAK KO causes OxSR1 to shift to a more punctate appearance. 
On NE stimulation, OxSR1 shifts substantially toward the apical 
membrane. NaCl cotransporter (NCC) is phosphorylated (P) on 
activation. DCT indicates distal convoluted tubule.
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not completely ameliorate the familial hyperkalemic hyper-
tension phenotype. Instead, the disruption of both OxSR1 and 
SPAK was necessary to return NCC phosphorylation, blood 
pressure, and plasma K+ back to normal. Grimm et al27 postu-
lated that OxSR1 requires SPAK to move to the apical mem-
brane, where it can phosphorylate NCC. The current results 
indicate that this deficiency can be overcome by adrenergic 
stimulation, because apical OxSR1 is abundant after stimula-
tion in SPAK−/− mice (Figure 8). Taken together, the results 
suggest complementary, but distinct, roles for SPAK and 
OxSR1 in regulating NCC. Clearly, SPAK is the dominant 
NCC-activating kinase under basal conditions, but OxSR1 
seems to predominate when the kidney responds to adrenergic 
stimulation. As suggested by Grimm et al,27 both kinases may 
be necessary to activate NCC to its fullest extent.
Guyton41 suggested that, although the kidney is an especially 
potent regulator of arterial pressure, these actions are slow. It 
has been surprising, therefore, to find that NCC is modulated 
acutely in a variety of circumstances. Acute hypertension, or 
angiotensin-converting enzyme inhibition, shifts NCC out of 
the plasma membrane22,34,42; acute KCl gavage rapidly reduces 
pNCC abundance.43 Here, we have shown that adrenergic stim-
ulation activates NCC rapidly and substantially. This response 
is most likely a part of the fight-or-flight reflex, described by 
Cannon,44 in which the maintenance of arterial pressure and 
essential organ perfusion provides short-term advantage. 
When this response is anomalously derived and maintained 
chronically, however, it likely contributes to pathological 
hypertension. There has been substantial disappointment that 
renal denervation did not prove effective in the large rigor-
ous SYMPLICITY HTN-3 trial for the treatment of resistant 
hypertension.14 Some commentators have suggested that one 
difference between the SYMPLICITY HTN-3 trial and earlier 
trials is the intense focus on appropriate medical management 
in the SYMPLICITY HTN-3.45 This focus included aggressive 
use of thiazide-type diuretics and aldosterone antagonists, both 
which inhibit NCC.46 Thus, these drugs may have achieved, 
medically, some of the effects that nerve ablation would other-
wise, rendering the intervention less effective.
Perspectives
The current work shows that adrenergic stimulation of 
β-receptors in DCT cells stimulates NCC, both acutely and 
chronically, contributing to salt-sensitive hypertension. This 
effect is mediated largely by OxSR1, rather than SPAK, 
identifying an essential and nonredundant role for OxSR1 in 
modulating NCC activity, a role that was previously unappre-
ciated. The results suggest that renal nerves exert important 
effects on the kidney by activating salt transport pathways to 
increase arterial pressure; for this reason, the benefits of inva-
sive procedures may not seem as great, when compared with 
a control group treated aggressively with drugs that block salt 
transport.
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What Is New? 
•	Adrenergic stimulation rapidly activates NaCl cotransporter in the distal 
tubule via β-adrenergic receptors, which are enriched in distal convolut-
ed tubule cells. The effect is not dependent on angiotensin II or STE20p-
related proline- and alanine-rich kinase and is largely mediated by the 
oxidative stress–response kinase 1. These effects seem to contribute 
importantly to salt-sensitive hypertension resulting from norepinephrine 
infusion.
What Is Relevant?
•	These findings help explain how excessive sympathetic nerve activity 
causes hypertension. They indicate that medical and device-based ap-
proaches to hypertension converge on common mechanisms.
Summary
Our data provide evidence for an in vivo β-adrenergic signaling 
cascade in the distal convoluted tubule. It is largely mediated by the 
oxidative stress–response kinase 1 and is relevant in the genera-
tion of salt-sensitive hypertension.
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Detailed	  Methods	  
Animals	  All	  animal	  studies	  were	  approved	  by	  Oregon	  Health	  and	  Science	  University's	  Institutional	  Animal	  Care	  and	  Usage	  Committee	  (Protocol	  IS918).	  All	  mice	  were	  male	  littermates	  (12–16	  weeks,	  25–30	  g)	  and	  had	  a	  C57Bl/6	  background.	  All	  strains	  are	  backcrossed	  to	  the	  appropriate	  wild-­‐type	  mice	  every	  10	  generations	  to	  maintain	  genetic	  backgrounds.	  SPAK-­‐/-­‐	  mice,21,22	  and	  Angiotensin	  II	  receptor	  type	  1a	  (AT1a)-­‐/-­‐	  mice23	  have	  all	  been	  reported	  previously.	  Doxycycline-­‐inducible	  kidney-­‐specific	  (KS)	  OxSR1-­‐/-­‐	  mice	  were	  generated	  by	  crossing	  mice	  that	  were	  homozygous	  for	  floxed	  OxSR1	  with	  loxP	  sites	  flanking	  the	  113	  bp	  exon	  2	  with	  mice	  that	  express	  both	  the	  reverse	  tetracycline	  transactivator	  (rtTA)	  under	  the	  control	  of	  the	  renal	  epithelial	  cell-­‐specific	  Pax8	  promoter24	  and	  the	  LC1	  transgene.25	  Wild-­‐type	  controls	  for	  the	  KS	  OxSR1-­‐/-­‐	  mice	  were	  those	  littermates	  that	  had	  two	  floxed	  OxSR1	  alleles,	  but	  lacked	  either	  the	  LC1	  transgene,	  the	  Pax8	  transgene,	  or	  both.	  Prior	  to	  use	  in	  reported	  studies,	  KS	  OxSR1-­‐/-­‐	  mice	  were	  treated	  with	  doxycyline	  (2	  mg/ml	  in	  5%	  sucrose	  in	  drinking	  water)	  for	  15	  days	  to	  induce	  Cre-­‐mediated	  recombination.	  Wild-­‐type	  controls	  also	  received	  doxycycline.	  	  
PCR	  Genotyping	  Standard	  PCR	  on	  tail	  snips	  was	  used	  for	  animal	  genotyping.	  For	  AT1a-­‐/-­‐	  mice,	  the	  following	  primers	  were	  used	  to	  distinguish	  knockout	  from	  wild-­‐type	  animals:	  5’-­‐TGAGAACACCAATATCACTG-­‐3’,	  5’-­‐TTCGTAGACAGGCTTGAG-­‐3’,	  and	  5’-­‐CCTTCTATCGCCTTCTTGACG-­‐3’.	  To	  distinguish	  mice	  carrying	  at	  least	  one	  modified	  SPAK	  allele	  from	  wild-­‐type	  mice,	  a	  previously	  reported	  approach	  was	  used.22	  Western	  blots	  on	  protein	  extracts	  from	  cultured	  tail	  cells	  were	  then	  used	  to	  further	  distinguish	  heterozygous	  SPAK	  mice	  from	  homozygous	  SPAK	  null	  mice.	  For	  KS	  OxSR1-­‐/-­‐	  mice,	  the	  following	  primers	  were	  used	  to	  identify	  animals	  that	  were	  homozygous	  for	  floxed	  exon	  2	  within	  the	  OxSR1	  gene	  and	  also	  carried	  at	  least	  one	  copy	  each	  of	  the	  Cre	  and	  Pax8	  rtTA	  transgenes:	  OxSR1FloxF:	  5’-­‐AGCTCAGGCTCCCTCCACGGAG,	  OxSR1FloxR:	  5’-­‐AAGACACATTGATACTCTGTTTCTCGAAGG;	  CreF:	  5’-­‐TTTCCCGCAGAACCTGAAGATG,	  CreR:	  5’-­‐TCACCGGCATCAACGTTTTCTT;	  Pax8F:	  5’-­‐CCATGTCTAGACTGGACAAGA,	  Pax8R:	  5’-­‐CAGAAAGTCTTGCCATGACT.	  	  
Animal	  studies	  Systolic	  blood	  pressures	  (SBPs)	  were	  measured	  with	  tail-­‐cuffs	  using	  volumetric	  pressure	  recording	  (CODA-­‐6;	  Kent	  Scientific).	  This	  method	  has	  been	  validated	  for	  SBP	  measurements	  in	  mice,	  showing	  correlation	  with	  radiotelemetry.26,27	  The	  mice	  were	  first	  acclimated	  to	  the	  experimental	  procedure	  for	  five	  consecutive	  days;	  baseline	  SBP	  was	  then	  measured	  for	  one	  week	  on	  normal	  salt	  (0.49%	  NaCl).	  At	  the	  start	  of	  the	  second	  week,	  NE	  (2.5	  mg/kg/d,	  Sigma)	  or	  vehicle	  was	  administered	  via	  osmotic	  minipump	  (Alzet)	  for	  two	  weeks	  while	  SBP	  measurements	  were	  continued.	  During	  the	  third	  week,	  all	  mice	  were	  switched	  to	  a	  high	  salt	  diet	  (8%	  NaCl,	  Harlan	  Teklad)	  and	  
SBP	  measurements	  were	  continued.	  For	  short-­‐term	  adrenergic	  stimulation	  studies,	  norepinephrine	  (1250	  ug/kg),	  phenylephrine	  (1250	  ug/kg),	  isoproterenol	  (1250	  ug/kg),	  or	  vehicle	  was	  injected	  intraperitoneally	  as	  indicated.	  	  	  
Immunoblotting	  Mouse	  kidneys	  were	  harvested	  and	  snap-­‐frozen	  in	  liquid	  nitrogen.	  Kidneys	  were	  then	  homogenized	  on	  ice	  in	  chilled	  homogenization	  buffer	  containing	  protease	  and	  phosphatase	  inhibitors.	  Protein	  (20–80	  μg)	  was	  separated	  on	  3–8%	  (wt/vol)	  Tris	  acetate	  or	  4-­‐12%	  (wt/vol)	  Bis-­‐Tris	  gel	  (Invitrogen).	  All	  primary	  antibodies	  have	  been	  characterized	  and	  were	  specific	  to	  the	  following	  proteins:	  NCC,	  pNCC	  at	  threonine-­‐53,	  and	  WNK4	  (developed	  in	  laboratory	  of	  DHE),	  pNCC	  at	  threonine-­‐58	  and	  pNCC	  at	  serine-­‐71	  (developed	  in	  laboratory	  of	  JL),	  SPAK,	  OxSR1,28	  β-­‐actin	  (Abcam).	  Densitometry	  was	  performed	  using	  ImageJ	  (http://rsbweb.nih.gov/ij/).	  All	  bands	  were	  normalized	  to	  actin.	  Representative	  images	  are	  shown.	  Densitometry	  is	  in	  the	  online	  supplement.	  	  	  
Immunofluorescence	  Mice	  were	  anesthetized	  with	  isoflurane	  and	  kidneys	  perfusion-­‐fixed	  by	  retrograde	  abdominal	  aortic	  perfusion	  of	  3%	  paraformaldehyde	  in	  PBS	  (pH	  7.4).	  After	  overnight	  cryoprotection	  with	  800	  mOsm	  sucrose	  and	  freezing,	  5	  μm	  sections	  were	  cut,	  washed	  in	  1×	  PBS,	  incubated	  in	  1×	  PBS	  with	  0.5%Triton	  X	  for	  30	  min,	  washed	  in	  PBS,	  and	  blocked	  in	  5%	  milk	  in	  PBS	  for	  30	  min.	  Primary	  antibody	  in	  5%	  milk	  in	  1×	  PBS	  was	  added	  for	  1	  hr,	  followed	  by	  a	  wash	  in	  PBS.	  Sections	  were	  incubated	  for	  45	  min	  with	  secondary	  antibody	  in	  block,	  then	  washed.	  Images	  were	  acquired	  on	  a	  high	  resolution	  wide	  field	  Core	  DV	  system	  (Applied	  Precision™).	  The	  system	  was	  an	  Olympus	  IX71	  inverted	  microscope	  with	  a	  proprietary	  XYZ	  stage	  enclosed	  in	  a	  controlled	  environment	  chamber;	  differential	  interference	  contrast	  (DIC)	  transmitted	  light	  and	  a	  solid	  state	  module	  for	  fluorescence.	  The	  camera	  used	  was	  a	  Nikon	  Coolsnap	  ES2	  HQ.	  Representative	  images	  are	  shown.	  	  	  
DCT-­‐Specific	  PCR	  
	   DCT	  cDNA	  was	  obtained	  from	  mice	  expressing	  the	  enhanced	  green	  fluorescent	  protein	  (EGFP)	  under	  the	  control	  of	  the	  parvalbumin	  promoter.	  	  GFP+	  tubule	  segments	  were	  isolated	  via	  a	  Complex	  Object	  Parametric	  Analyzer	  and	  Sorter	  (COPAS)	  and	  RNA	  and	  cDNA	  were	  prepared	  all	  as	  described	  previously.29	  The	  following	  primers	  were	  used	  were	  for	  the	  designated	  RT-­‐PCR	  reactions.	  β1-­‐adrenergic	  receptor	  forward:	  5’-­‐ATCGTTCTGCTCATCGTGGTGGGTAACG,	  β1-­‐adrenergic	  receptor	  reverse:	  5’-­‐CGTCAGCAAACTCTGGTAGCGAAAGGG;	  β2-­‐adrenergic	  receptor	  forward:	  5’-­‐ATGGGGCCACACGGGAACGAC,	  β2-­‐adrenergic	  receptor	  reverse:	  5’-­‐	  GGCGTAGGCCTGGTTCGTGAAGAAGTC;	  NCC	  forward:	  5’-­‐TCACCATCAGCACACTGATGGGAGG,	  NCC	  reverse:	  5’-­‐ATCACTCCCCAGATGTTGAGCATGCAAC;	  AQP2	  forward:	  5’-­‐	  
GAGATTACCCCTGTAGAAATCCGCGGGG,	  AQP2	  reverse:	  5’-­‐	  GGGTCCGATCCAGAAGACCCAGTGATC;	  GAPDH	  forward:	  5’-­‐ATGGTGAAGGTCGGTGTGAACGGATTTG,	  GAPDH	  reverse:	  5’-­‐	  GCCTTCTCCATGGTGGTGAAGACACCAG.	  	  
Ex	  vivo	  stimulation	  of	  COPAS-­‐sorted	  DCT	  with	  Isoproterenol	  
	   DCTs	  were	  sorted	  with	  COPAS	  from	  one	  mouse	  expressing	  the	  enhanced	  green	  fluorescent	  protein	  (EGFP)	  under	  the	  control	  of	  the	  parvalbumin	  promoter	  as	  described	  previously29.	  Per	  condition,	  1000	  DCTs	  were	  sorted	  into	  35	  mm	  Petri	  dishes	  (on	  ice)	  in	  an	  alternating	  manner	  (control,	  isoproterenol,	  control,	  isoproterenol,	  etc.)	  to	  avoid	  time-­‐dependent	  sorting	  effects.	  Once	  1000	  DCTs	  per	  condition	  were	  sorted,	  Petri	  dishes	  were	  placed	  in	  an	  incubator	  for	  5	  min	  until	  37°C	  were	  reached.	  Cells	  were	  then	  stimulated	  with	  either	  vehicle	  or	  100	  nM	  isoproterenol	  (DL-­‐isoproterenol	  hydrochloride,	  Sigma)	  at	  37°C	  for	  10	  min.	  The	  supernatant	  was	  collected	  and	  the	  remaining	  cells	  washed	  off	  the	  petri	  dish	  with	  ice	  cold	  KREBS	  and	  collected	  as	  well.	  Cells	  were	  spun	  at	  800xg,	  4°C	  for	  5	  min	  and	  the	  pellet	  re-­‐disolved	  in	  30	  ul	  1x	  Laemmli.	  500	  tubules	  were	  loaded	  on	  a	  10	  %	  SDS	  PAGE	  to	  detect	  either	  NCC	  or	  pNCC.	  	  
Statistical	  Analyses	  Unpaired	  t-­‐tests	  were	  used	  to	  compare	  groups.	  p<0.05	  was	  considered	  significant.	  	  When	  necessary,	  corrections	  for	  multiple	  comparisons	  were	  used	  as	  indicated.	  	  	  Two-­‐way	  ANOVA	  with	  repeated	  measures	  was	  used	  to	  compare	  blood	  pressure	  across	  time	  in	  vehicle-­‐	  and	  norepinephrine-­‐treated	  mice.	  	  
	  
	  
	   	  
Supplemental	  Figure	  Legends	  
	  
S1:	  Western	  blot	  quantification	  for	  chronic	  NE	  treatment.	  Panel	  A:	  Chronic	  NE	  treatment	  increased	  NCC	  abundance.	  Panel	  B:	  Chronic	  NE	  treatment	  increased	  pNCC-­‐T53	  abundance.	  Panel	  C:	  WNK4	  abundance	  was	  unchanged	  by	  chronic	  NE	  treatment.	  Graphs	  depict	  mean	  ±	  s.e.m.	  *	  p<0.05	  by	  unpaired	  t-­‐test.	  	  	  	  
S2:	  Western	  blot	  quantification	  for	  acute	  NE	  treatment.	  Panel	  A:	  Treatment	  with	  NE	  for	  30	  minutes	  increased	  pNCC-­‐T53	  abundance.	  Panel	  B:	  Treatment	  with	  NE	  for	  30	  minutes	  did	  not	  change	  NCC	  abundance.	  Panel	  C:	  Treatment	  with	  NE	  for	  30	  minutes	  also	  increased	  pNCC-­‐T58	  and	  pNCC-­‐S71	  abundance.	  Panel	  D:	  Immunoblot	  quantification	  for	  pNCC-­‐T58	  abundance.	  
Panel	  E:	  Immunoblot	  quantification	  for	  pNCC-­‐S71	  abundance.	  Panel	  F:	  pNCC	  abundance	  in	  AT1a-­‐/-­‐	  mice	  is	  not	  statistically	  different	  from	  wild-­‐type	  controls.	  Panel	  G:	  NCC	  abundance	  in	  AT1a-­‐/-­‐	  mice	  is	  not	  statistically	  different	  from	  wild-­‐type	  controls.	  Panel	  H:	  Treatment	  with	  NE	  for	  30	  minutes	  increased	  pNCC-­‐T53	  abundance	  in	  AT1a-­‐/-­‐	  mice.	  Panel	  I:	  Treatment	  with	  NE	  for	  30	  minutes	  did	  not	  change	  NCC	  abundance	  in	  AT1a-­‐/-­‐	  mice.	  Graphs	  depict	  mean	  ±	  s.e.m.	  *	  p<0.05	  by	  unpaired	  t-­‐test.	  	  	  
	  
S3:	  Western	  blot	  quantification	  for	  acute	  PE	  and	  Iso	  treatment.	  Panel	  A:	  Treatment	  with	  the	  α-­‐receptor	  agonist,	  phenylephrine	  (PE),	  for	  30	  minutes	  did	  not	  significantly	  increase	  pNCC-­‐T53	  abundace.	  Panel	  B:	  Treatment	  with	  PE	  for	  30	  minutes	  did	  not	  change	  NCC	  abundance.	  Panel	  C:	  Treatment	  with	  the	  β-­‐receptors	  agonist,	  isoproterenol	  (Iso),	  for	  30	  minutes	  significantly	  increased	  pNCC-­‐T53	  abundance.	  Panel	  D:	  Treatment	  with	  Iso	  for	  30	  minutes	  did	  not	  change	  NCC	  abundance.	  Panel	  E:	  Treatment	  with	  both	  agonists	  together	  increased	  pNCC-­‐T53	  abundance	  greater	  than	  either	  agonist	  alone.	  
Panel	  F:	  Treatment	  with	  both	  agonists	  together	  did	  not	  alter	  NCC	  abundance.	  Graphs	  depict	  mean	  ±	  s.e.m.	  *	  p<0.05	  by	  unpaired	  t-­‐test.	  #	  p<0.016	  by	  unpaired	  t-­‐test.	  	  
	  
	  
	   	  
	  
	  
S4:	  Western	  blot	  quantification	  for	  acute	  NE	  treatment	  in	  SPAK-­‐/-­‐	  mice.	  
Panel	  A:	  Treatment	  with	  NE	  for	  30	  minutes	  did	  not	  change	  SPAK	  abundance	  in	  wild-­‐type	  mice.	  Panel	  B:	  Treatment	  with	  NE	  for	  30	  minutes	  increased	  pNCC-­‐T53	  abundance	  in	  SPAK-­‐/-­‐	  mice.	  Panel	  C:	  Treatment	  with	  NE	  for	  30	  minutes	  increased	  pNCC-­‐T53	  abundance	  in	  SPAK-­‐/-­‐	  mice	  greater	  than	  in	  wild-­‐type	  controls.	  Graphs	  depict	  mean	  ±	  s.e.m.	  *	  p<0.05	  by	  unpaired	  t-­‐test.	  
	  
	  
	  
	  
	  
	  
	  
S5:	  Western	  blot	  quantification	  for	  acute	  NE	  treatment	  in	  KS	  OxSR1-­‐/-­‐	  
mice.	  Panel	  A:	  KS	  OxSR1-­‐/-­‐	  mice	  had	  significantly	  decreased	  abundance	  of	  OxSR1	  in	  their	  kidneys	  compared	  with	  wild-­‐type	  controls.	  Panel	  B:	  The	  abundance	  of	  pNCC-­‐T53	  was	  unaltered	  in	  KS	  OxSR1-­‐/-­‐	  mice	  at	  baseline.	  Panel	  
C:	  The	  abundance	  of	  NCC	  protein	  was	  unaltered	  in	  KS	  OxSR1-­‐/-­‐	  mice	  at	  baseline.	  Panel	  D:	  Treatment	  with	  NE	  for	  30	  minutes	  increased	  pNCC-­‐T53	  abundance	  in	  KS	  OxSR1-­‐/-­‐	  mice.	  Panel	  E:	  Treatment	  with	  NE	  for	  30	  minutes	  increased	  pNCC-­‐T53	  abundance	  in	  KS	  OxSR1-­‐/-­‐	  mice	  less	  than	  in	  wild-­‐type	  controls.	  Graphs	  depict	  mean	  ±	  s.e.m.	  *	  p<0.05	  by	  unpaired	  t-­‐test.	  
	  
	  
	  
	  
	  
	   	  
Supplemental	  Movie	  1:	  NE	  increased	  DCT	  OxSR1	  apical	  localization	  in	  
SPAK-­‐/-­‐	  mice.	  Treatment	  with	  NE	  for	  30	  minutes	  increased	  the	  apical	  localization	  of	  OxSR1	  in	  the	  DCT	  of	  SPAK-­‐/-­‐	  mice.	  	   	  	  
